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Abstract
We previously discovered that a polymorphic, deoxythymidine-homopolymer (poly-T, rs10524523) in intron 6 of the
TOMM40 gene is associated with age-of-onset of Alzheimer’s disease and with cognitive performance in elderly. Three allele
groups were defined for rs10524523, hereafter ‘523’, based on the number of ‘T’-residues: ‘Short’ (S, T#19), ‘Long’ (L,
20#T#29) and ‘Very Long’ (VL, T$30). Homopolymers, particularly long homopolymers like ‘523’, are difficult to genotype
because ‘slippage’ occurs during PCR-amplification. We initially genotyped this locus by PCR-amplification followed by
Sanger-sequencing. However, we recognized the need to develop a higher-throughput genotyping method that is also
accurate and reliable. Here we describe a new ‘523’ genotyping assay that is simple and inexpensive to perform in a
standard molecular genetics laboratory. The assay is based on the detection of differences in PCR-fragment length using
capillary electrophoresis. We discuss technical problems, solutions, and the steps taken for validation. We employed the
novel assay to investigate the ‘523’ allele frequencies in different ethnicities. Whites and Hispanics have similar frequencies
of S/L/VL alleles (0.45/0.11/0.44 and 0.43/0.09/0.48, respectively). In African-Americans, the frequency of the L-allele (0.10) is
similar to Whites and Hispanics; however, the S-allele is more prevalent (0.65) and the VL-allele is concomitantly less
frequent (0.25). The allele frequencies determined using the new methodology are compared to previous reports for
Ghanaian, Japanese, Korean and Han Chinese cohorts. Finally, we studied the linkage pattern between TOMM40-‘523’ and
APOE alleles. In Whites and Hispanics, consistent with previous reports, the L is primarily linked to e4, while the majority of
the VL and S are linked to e3. Interestingly, in African-Americans, Ghanaians and Japanese, there is an increased frequency of
the ‘523’S-APOEe4 haplotype. These data may be used as references for ‘523’ allele and ‘523’-APOE haplotype frequencies in
diverse populations for the design of research studies and clinical trials.
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Introduction
Rs10524523 polymorphism, hereafter ‘523’, is a variable length,
deoxythymidine homopolymer located in chromosome 19 at
position 45403049 (Genome Build 37.1) within intron 6 of the
TOMM40 gene (Ensembl: ENSG00000130204). TOMM40 en-
codes the essential mitochondrial protein import translocase
(Translocase of the Outer Mitochondrial Membrane, 40 kD),
and is adjacent to, and in linkage disequilibrium with, the
apolipoprotein E (APOE) gene (Ensembl: ENSG00000130203). In
the human reference sequence, the number of ‘T’ residues in
the homopolymer is 35, and the variant allele described by
rs10524523 is a 19 bp deletion (i.e. the variant allele is 16 T
residues).
Using a deep sequencing and phylogenetic analysis approach,
Roses et al. discovered that TOMM40 ‘523’ contributes to the
genetic risk and age of onset of late onset Alzheimer’s disease
(LOAD, MIM 104310) in APOEe 3/4 patients [1]. This
polymorphism may explain some of the genetic association with
age of disease onset previously attributed solely to APOE [1,2]. A
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T), which may be binned into three major allelic groups according
to the length distribution profiles: ‘Short’ (S, T#19), ‘Long’
(L, 20#T#29) and ‘Very Long’ (VL, T$30). [1,2].
There is accumulating evidence that the poly-T locus in
TOMM40 is associated with progression to Alzheimer’s disease
(AD). The L and VL alleles are significantly associated with earlier
age of disease onset in subjects carrying APOE e3/4 [1,2] (,7
years earlier onset in VL/L vs. S/L) and APOE e3/3 [3] (,9 years
earlier onset in VL/VL vs. S/S) genotypes. Johnson et al. described
the association of VL alleles of ‘523’ with impaired verbal memory
recall, known to be affected in the early stages of AD, in APOE e3/
3 subjects drawn from a clinically normal, late middle-aged cohort
enriched for family history of AD [4]. Moreover, in a
neuroimaging analysis of a subset of this APOE e3/3 cohort,
Johnson et al. demonstrated a significant association between ‘523’
VL and reduced gray matter volume, measured by MRI, in areas
of the brain known to be affected in the early stages of AD [4].
More recently, an association between cognitive performance in
cognitively normal elderly and ‘523’ genotype was identified; the
‘523’ variant was associated with neuropsychological measures
that are preferentially affected in early stage AD (Hayden et. al.
Alzheimer’s and Dementia, in press).
Ongoing basic researchinto thebiological significance of the ‘523’
poly-T locus and its potential for use in a clinical trial setting [5]
inspired the need to develop a genotyping assay that is simpler and
less expensive than the Sanger sequencing method that was used
previously [1,2,4]. We have developed an assay that is sufficiently
simple, inexpensive and robust to perform in a standard molecular
geneticslaboratory. Wehaveused this assay to determine ‘523’ allele
and ‘523’-APOE haplotype frequencies in diverse populations.
Materials and Methods
Subjects
Assay validation cohorts. DNA samples generously pro-
vided by the Kathleen Price Bryan Brain Bank (KPBBB) at Duke
University. The assay was validated in three sample sets using a
total of 140 DNA samples, 40 from brain tissue and 100 from
blood. The Duke University Health System Institutional Review
Board for Clinical Investigations granted approval for use of the
Bryan ADRC Database/Repository.
Ethnic cohorts. White (of European descent): 177 individuals
(,70% females) from five local independent-living retirement
communities in the Research Triangle Park region of North
Carolina. The average age at recruitment was 80.466.1 (age
range 63–95). DNA was extracted from saliva samples. This
project was approved by the Duke Institutional Review Board.
African American: This group comprised 370 individuals (,78%
were females) sampled from 29 different independent housing
buildings in Baltimore MD. The average age was 71.9069.06 (age
range 52–96). DNA was extracted from saliva samples. This project
was approved by the Duke Institutional Review Board.
Hispanic: This group comprised 179 subjects (,75% females)
from Proyecto SALSA, a clinic-based sample of low-income
Mexican Americans from San Diego County ascertained between
2003–2005. The average age of the adult Latino participants of
that study was 54 years old. Blood samples were collected for DNA
extraction. The project was approved by IRBs at San Diego State
University and Duke University [6].
DNA extraction
Saliva sample collection and DNA extraction were performed
using the commercially available Oragene DNA Self-Collection
Kit (DNA Genotek Inc., Kanata, Ontario, Canada) according to
the manufacture’s protocol. DNA extractions from blood and
brain tissue were performed using the QIAamp DNA kit by the
standard Qiagen protocol (Qiagen Valencia, CA, USA). DNA
concentration and the quality of purification were determined
spectrophotometrically.
TOMM40 poly-T rs10524523 genotyping assay
Each genomic DNA sample (10–20 ng) was PCR amplified
using fluorescently labeled forward 59FAM-TGCTGACCTCAA
GCTGTCCTC-39 and reverse 59-GAGGCTGAGAAGGGAG-
GATT-39primers (each 0.4 mM). The PCR amplification was
carried out by TaKaRa EX Taq polymerase (Takara Bio Inc.,
Otsu, Shiga, Japan) in the presence of 5% fresh DMSO and under
the following conditions: 3 min at 94uC, then 27 cycleswith 15 s at
94uC, 20 s at 65uC, and 30 s at 70uC; concluded with 5 min at
70uC. At completion, the reaction mix was maintained at 4uC.
Whereas ‘N’ represents the number of the poly-T residues, the
expected length of the PCR product is N+150 bp (the poly-T
flanking region and an ‘A’ overhang at the end of the product).
Two ml of each PCR product, 7.5 ml of Hi-Di Formamide
(Applied Biosystems, Foster City, CA) and 0.5 ml of Size Standard
(GeneScan 500LIZ; Applied Biosystems, Foster City, CA) were
denatured at 95uC for 3 min, immediately chilled in an ice water
bath for 10 min, and loaded on an ABI 3730 DNA Analyzer.
Genotypes were determined on an ABI 3730 using GeneMapper
version 4.0 software (Applied Biosystems, Foster City, CA) for
fragment analysis by the amplified fragment length polymorphism
(AFLP) method. The ‘523’ alleles were called according to the
length of the PCR product. The convention established by Roses et
al. for determining alleles was used: Short (S), #19; Long (L) 220–
29; Very Long (VL) $30 [1,2].
APOE genotyping
APOE genotypes were determined using a TaqMan-based allelic
discrimination assay (Applied Biosystems). Briefly, APOE e2/3/4
genotypes were established using two separate SNPs: (1) rs429358
334T/C (ABI assay ID: C_3084793_20), and (2) rs7412 472T/C
(ABI assay ID: C_904973_10). The assays were conducted on a
ABI 7900HT and genotype analysis was performed by the SNP
auto-caller feature of SDS software. APOE genotypes were
assigned as described previously [7].
Results and Discussion
We have developed a genotyping assay that uses PCR am-
plification of the ‘523’ poly-T region followed by capillary
electrophoresis of the PCR products to size the DNA fragments.
The automated ABI 3730 sequencing platform yielded accurate
sizing results with single-base resolution.
Technical issues and solutions
Homopolymers and other Simple Polymeric Repeats (SPRs) are
notoriously difficult to analyze, particularly with methods that
employ PCR. The problem is that a significant amount of
‘slippage’ may occur during each DNA amplification cycle,
causing the newly polymerized strand to have either fewer or
more residues than the original template strand. After several
cycles of PCR, the amplification product contains a complex
mixture of PCR amplicons that vary in length at the poly-T locus
and include amplicons with the true poly-T length. Each PCR
sample, containing all amplicons, is analyzed by capillary
electrophoresis to determine amplicon length. The polymerase
‘slippage’ is not completely avoidable, therefore the biggest hurdle
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electropherograms produced by capillary electrophoresis of the
PCR products in order to determine precisely the original
template length and thus the true poly-T length. To circumvent
this problem, we took advantage of that fact that the lengths of the
PCR amplicons are normally distributed (i.e. each electrophero-
gram shows a cluster of peaks, due to slippage at the poly-T locus,
with a normal distribution of peak heights). We assumed that the
true amplicon length had the highest frequency in the mixture of
PCR-product lengths, reflected by the highest intensity peak
within the cluster (i.e. the fragment length of the highest peak, or
the Mode value, indicates the original (pre-PCR) fragment length).
The automated analysis of the fragment lengths might introduce
61 bp sizing differences in calling the absolute product length
between runs. To overcome this issue we included consistent
calibration standards in each run. These calibration samples, one
for each ‘523’ allele category, were selected from a set of DNA
samples with known poly-T lengths that were determined by direct
Sanger sequencing (of multiple PCR clones). The calibration
standards are included as parallel reactions subjected to the same
PCR conditions and capillary electrophoresis, and used as
reference controls for each run.
Assay validation
Validation checks were performed in three stages: 1) using DNA
from twelve subjects (extracted from 8 blood and 4 brain samples)
an open comparison was made between the results of the new
electrophoretic assay and the results of direct Sanger sequencing
obtained by sequencing multiple clones of PCR products
containing the ‘523’ poly-T (conducted by Polymorphic, Inc.)
[1,2]. The two methods agreed, for all allele categories (S/L/VL),
with a maximum length deviation of 61 bp. 2) 36 DNA samples
extracted from brain tissue were used in a blinded comparison of
the results of the new electrophoretic assay with the results of the
Sanger sequencing-based assay (conducted by Polymorphic, Inc.).
There was 100% concordance, as scored by a third party. 3) In a
second blinded comparison we used 72 different DNA samples
extracted from blood of subjects with the APOE e3/4 genotype.
DNA samples were genotyped for the ‘523’ polymorphism by the
new electrophoretic assay and compared to the results obtained by
the Sanger sequencing-based assay (conducted by Polymorphic,
Inc.). In this test, there was 93% (67/72) concordance for ‘523’
genotype calls (using the S, L, VL categories) between the two
methods. Numerical poly-T lengths were concordant 90% (129/
144) of the time, where concordance was a difference of 0 or 61
‘T’ residue. The mean difference in allele length between the two
assays was 1.1 (SD 1.9). It should be noted that both assays use
PCR as a first step which may introduce variability that originated
from ‘slippage’ as described above.
Allele frequencies in diverse populations
The electrophoretic genotyping assay was employed to
determine ‘523’ allele frequencies in diverse populations residing
in the United States. Three races or ethnicities were investigated:
Whites (individuals of European descent), African Americans, and
Hispanics. Whites and Hispanics had similar allele distributions,
which differed from the distribution in African Americans
(Table 1). While the frequency of the L allele was similar across
the different groups (9–11%), the frequencies of the S and VL
alleles differed. In Whites and Hispanics, the S and VL alleles were
common with similar frequencies (45% and 44%, respectively and
43% and 48%, respectively), but in African Americans the S allele
was the most common (65%) and the VL allele was relatively less
frequent (25%) (Table 1).
The poly-T tracts ranged from 14 to 54 T residues (Table 1)
taking into account all populations. Interestingly, the much longer
homopolymers were noted in the African American group
compared to the other groups studied (poly-T lengths up to 54
residues were seen in the African American group vs. 39 T
residues in Whites and Hispanics, Table 1). These ’523’ allele
distributions for the US populations were compared to previous
results from Ghanaian, Japanese, Korean and Han Chinese
cohorts(Table 2) [8]. ‘523’ allele frequencies for the Ghanaian
cohort were most similar to the African American cohort, but
there was an even greater enrichment for the S allele in the
Ghanaian sample (71% for Ghanaian, 65% for African American).
Interestingly, the Far Eastern cohorts (Japanese, Korean and Han
Chinese) were enriched for the VL allele when compared to
Whites and African Americans (52–72% for Far Eastern cohorts,
44% for Whites, 25% for African Americans) with a concomitant
decrease in the frequency of the S allele (20–38% for the Far
Eastern cohorts, 45% for Whites, 65% for African Americans).
TOMM40 and APOE, are adjacent genes on chromosome 19
and are in high linkage disequilibrium (LD). We investigated the
linkage between the ‘523’ alleles (S, L, VL) and the different alleles
of APOE (e2, e3, or e4). Table 3 presents the APOE allele
frequencies for each ‘523’ genotype group. In Whites, the L allele
most frequently co-occurs with e4, while the majority of the VL
and S alleles co-occur with e3 (Table 3). This observation is
consistent with the previous reports in White populations [1,2]. A
relatively similar frequency of APOE-‘523’ haplotypes was
observed with the Hispanic population (Table 3). It is very
important to note that, unlike the White populations (this study
and previous reports) and the Hispanic population, the African
Americans showed a significant number of e4 alleles in the S/S
subjects group (,13% of the S alleles, Table 3). This result
indicates that the S and the e4 alleles were linked relatively
frequently in the African American population. We also observed
a relative higher frequency of e4 allele in the VL containing
genotypes in African-Americans compared to Whites and
Table 1. ‘523’ Allele frequencies in different ethnicities in the
US.
Ethnicity Subjects(N) S (%) L(%) VL(%) Poly T length (range)
Whites 177 45 11 44 14–39
African
American
370 65 10 25 14–54
Hispanic 179 43 9 48 14–39
doi:10.1371/journal.pone.0030994.t001
Table 2. ‘523’ Allele frequencies in non US geographical
cohorts (Far Eastern and West Africa).
Ethnicity Subjects(N) S (%) L(%) VL(%) Poly T length (range)
Ghanaian 40 71 8 21 13–43
Japanese 60 24 18 58 11–35
Korean 60 20 8 72 11–38
Han
Chinese
60 38 10 52 12–36
Genotypes determination was performed by Polymorphic, Inc. using a
sequencing based assay.
doi:10.1371/journal.pone.0030994.t002
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that the e4-VL haplotype is more frequent in the African
Americans compared to the other populations. These ‘523’-
APOE alleles haplotype frequencies for the US populations were
compared to previous results from Ghanaian, Japanese, Korean
and Han Chinese cohorts (Table 4) [8]. Consistent with the
African Americans, the Ghanaian population also showed
enrichment of e4 alleles in S-containing genotypes (Table 4).
Also, although the number of VL genotypes in the Ghanaian
subjects was very small, the e4-VL haplotype is likely at
relatively higher frequency (Table 4). Among the Far Eastern
cohorts the Korean and Han Chinese showed a similar allelic
distribution to that observed in the White and Hispanic cohorts
(Table 4). Interestingly, the haplotype data of the Japanese
implied more frequent occurrence of APOE e4-S haplotypes,
similar to the observation with the African American and
Ghanaian samples.
The unique distribution of allele frequencies, differences in the
poly-T lengths within each allele group, and the inferred
differences in the linkage patterns between ‘523’ and APOE alleles
emphasize the importance of extending this study to additional
ethnic groups in the US and worldwide. It will be valuable to have
direct measurement of the ‘523’-APOE haplotype frequencies in
diverse groups.
The data will serve as standard references for ‘523’ allele
frequencies in diverse populations for subsequent research studies,
including investigations of age of onset of AD and/or cognitive
decline in different ethnicities, and for future clinical trials.
Table 3. APOE allele frequencies by ‘523’ genotypes in different ethnicities in the US.
523
genotype S/S L/L VL/VL S/L S/VL L/VL
White Subjects N 34 3 37 22 70 11
APOE e4 0 (0) 6 (100) 2 (3) 21 (.48) 2 (1) 9 (41)
alleles e3 63 (93) 0 (0) 62 (84) 21 (.48) 126 (90) 13 (59)
n (%) e2 5 (7) 0 (0) 10 (13) 2 (4) 12 (9) 0 (0)
African American Subjects N 153 2 22 49 127 17
APOE e4 38 (12) 4 (100) 6 (14) 52 (53) 35 (14) 18 (53)
alleles e3 225 (74) 0 (0) 37 (84) 39 (40) 202 (79) 16 (47)
n (%) e2 43 (14) 0 (0) 1 (2) 7 (7) 17 (7) 0 (0)
Hispanic Subjects N 34 3 39 10 77 16
APOE e4 2 (3) 6 (100) 7 (9) 8 (40) 8 (5) 16 (50)
alleles e3 64 (94) 0 (0) 71 (91) 12 (60) 140 (91) 16 (50)
n (%) e2 2 (3) 0 (0) 0 (0) 0 (0) 6 (4) 0 (0)
doi:10.1371/journal.pone.0030994.t003
Table 4. APOE allele frequencies by ‘523’ genotypes in non US geographical cohorts (Far Eastern and West Africa).
523
genotype S/S L/L VL/VL S/L S/VL L/VL
Ghanaian Subjects N 21 0 3 5 10 1
APOE e4 3 (7) 0 (0) 1 (17) 4 (40) 5 (25) 2 (100)
alleles e3 28 (67) 0 (0) 4 (66) 5 (50) 10 (50) 0 (0)
n (%) e2 11 (26) 0 (0) 1 (17) 1 (10) 5 (25) 0 (0)
Japanese Subjects N 2 2 24 10 15 7
APOE e4 2 (50) 4 (100) 0 (0) 6 (30) 3 (10) 3 (21)
alleles e3 1 (25) 0 (0) 48 (100) 13 (65) 26 (87) 11 (79)
n (%) e2 1 (25) 0 (0) 0 (0) 1 (5) 1 (3) 0 (0)
Korean Subjects N 2 0 30 2 18 8
APOE e4 0 (0) 0 (0) 0 (0) 1 (25) 1 (3) 7 (44)
alleles e3 4 (100) 0 (0) 60 (100) 3 (75) 30 (83) 9 (56)
n (%) e2 0 (0) 0 (0) 0 (0) 0 (0) 5 (14) 0 (0)
Han Chinese Subjects N 7 1 15 4 27 6
APOE e4 0 (0) 2 (100) 0 (0) 3 (37.5) 1 (2) 5 (42)
alleles e3 10 (71) 0 (0) 29 (97) 2 (.25) 46 (85) 7 (58)
n (%) e2 4 (29) 0 (0) 1 (3) 3 (37.5) 7 (13) 0 (0)
Genotypes determination was performed by Polymorphic, Inc.
doi:10.1371/journal.pone.0030994.t004
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Since Roses et al. discovered the association between ‘523’ and
age of LOAD onset [1,2], a number of studies have also examined
this locus. Caselli et al. replicated the association between the
longer ‘523’ alleles and earlier onset of LOAD in an independent
group composed of APOE e3/3 subjects drawn from a longitudinal
study [3]. Furthermore, Johnson et al. reported significant
association of ‘523’ with impaired cognition and brain atrophy
in a clinically normal, late middle-aged cohort of APOE e3/3
subjects drawn from a population enriched for family history of
LOAD. In this cohort, the ‘523’ VL allele was significantly
associated with worse performance on primacy retrieval from a
verbal list learning task and with reduced gray matter volume in
ventral posterior cingulate and medial ventral precuneus, both
known to be affected in early AD [4]. In a cross sectional study of
cognitively healthy elderly, we have also observed APOE-
independent associations between the ‘523’ polymorphism and
specific cognitive domains of memory and executive control that
are preferentially affected in early stage AD (Hayden et. al.
Alzheimer’s and Dementia, in press). Together with the original
findings, these new studies establish, in Whites, the importance of
‘523’ in AD pathogenesis, particularly for APOE e3 carriers.
However, there are conflicting reports. While Chu et al. did not
replicate the association between ‘523’ and age of AD onset [9],
Cruchaga et al. replicated the association between the ‘523’ and
AD in APOE e3/3 subjects, but found that the S allele, rather than
the VL allele, was associated with increased AD risk; i.e. APOE e3/
3 subjects who carried the S/S genotype showed a trend towards
earlier age of onset [10]. Maruszak et. al. observed a significant
association between ‘523’ and LOAD risk, but reported that the
e3-VL haplotype is significantly more frequent among patients
with a later age of onset ($79 years) contrary to the prediction of
the original report [11]. Roses commented on these conflicting
observations and has proposed that there is a further subdivision of
VL subjects, with one VL subgroup falling prey to very early onset
disease ([12] and unpublished data). Some of the discrepancies
between the studies might be explained by the method used to
ascertain the age of onset. Different results may be attributed to
issues associated with study design, e.g. prospective versus
retrospective, longitudinal versus cross-sectional [1,2] [3] [10,11]
[12]. The differences in the results could also be related to
technical limitations and quality control of the ‘523’ genotyping
assay. Well-powered, longitudinal studies in diverse populations
with careful determination of age of onset using established criteria
and accurate genotypes determined by a validated method are
needed. This paper presents one part of the solution – a validated,
high-throughput assay for accurate determination of ‘523’ allele
length.
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